In our webinar titled “Antibacterial drugs: Clinical development for non-developers Part 1: Traditional development – tiers A and B” with David Shlaes, we received more questions from the audience than we could answer during the session. See below one of the open audience questions.
There are two problems with NTAP that discourage hospitals in the US from availing themselves of this money. NTAP only provides for 50% of the hospital cost. The bureaucratic paperwork requirements are burdensome. So for expensive antibiotics, hospitals are reluctant to bother with NTAP.
Viewing 2 posts - 1 through 2 (of 2 total)
You must be logged in to reply to this topic.